INO-3112 vaccine + Cisplatin chemotherapy
Phase 2Withdrawn 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Uterine Cervical Neoplasms
Conditions
Uterine Cervical Neoplasms
Trial Timeline
May 1, 2016 → May 1, 2021
NCT ID
NCT02501278About INO-3112 vaccine + Cisplatin chemotherapy
INO-3112 vaccine + Cisplatin chemotherapy is a phase 2 stage product being developed by Inovio Pharmaceuticals for Uterine Cervical Neoplasms. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT02501278. Target conditions include Uterine Cervical Neoplasms.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02501278 | Phase 2 | Withdrawn |
Competing Products
20 competing products in Uterine Cervical Neoplasms